# BioCity Group

> BioCity Group is a VC fund in Nottingham backing Biotechnology, Medical and Biopharma. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Nottingham, United Kingdom
- Total investments: 6
- Last investment: Jul 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/biocity-nottingham
- X (Twitter): http://twitter.com/BioCity_Nottm
- Website: http://www.biocity.co.uk/
- Facebook: http://www.facebook.com/BioCityNottm

BioCity Group is a business incubator that aides in the creation and development of life science businesses.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Medical | 2 | 33% |
| Biopharma | 2 | 33% |
| Therapeutics | 2 | 33% |
| Health Care | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Venture - Series Unknown | 2 | 33% |
| Series A | 1 | 17% |
| Funding Round | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 67% |
| United States | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NanoSyrinx | NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy. | $8.5M | Seed | Jul 19, 2021 |  |
| Rinri Therapeutics | Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients. | $12M | Venture - Series Unknown | Apr 20, 2021 |  |
| Maxwellia | Maxwellia is a pioneering ‘prescription to over the counter’ medicines company which specialises in ‘switching’ - the conversion of prescription medicines into branded versions that can be bought without a prescription, over the counter (OTC). | $4.4M | Venture - Series Unknown | Apr 08, 2021 |  |
| Kinomica | Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.1M | Series A | Dec 14, 2020 |  |
| NuVision | NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham. | $1.8M |  | Sep 12, 2019 |  |
| Rinri Therapeutics | Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients. | $1.8M | Seed | May 20, 2019 |  |

6 of 6 investments shown.

## Co-investors
- [Alderley Park Ventures](https://shizune.co/investors/profile/alderley-park-ventures) — VC Fund, 2 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together
- [The Future Fund](https://shizune.co/investors/profile/the-future-fund) — VC Fund, 2 deals together
- [UCB Ventures](https://shizune.co/investors/profile/ucb-ventures) — VC Fund, 2 deals together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 1 deal together
- [Catapult Ventures](https://shizune.co/investors/profile/catapult-venture-managers) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does BioCity Group invest in?

BioCity Group invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did BioCity Group last invest?

The most recent investment recorded for BioCity Group closed in Jul 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co